<?xml version='1.0' encoding='utf-8'?>
<document id="28513969"><sentence text="Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover Study."><entity charOffset="58-70" id="DDI-PubMed.28513969.s1.e0" text="Atorvastatin" /><entity charOffset="74-86" id="DDI-PubMed.28513969.s1.e1" text="Rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.28513969.s1.e0" e2="DDI-PubMed.28513969.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28513969.s1.e0" e2="DDI-PubMed.28513969.s1.e1" /></sentence><sentence text="Faldaprevir (FDV) is a potent, orally administered inhibitor of hepatitis C virus protease"><entity charOffset="0-11" id="DDI-PubMed.28513969.s2.e0" text="Faldaprevir" /><entity charOffset="13-16" id="DDI-PubMed.28513969.s2.e1" text="FDV" /><pair ddi="false" e1="DDI-PubMed.28513969.s2.e0" e2="DDI-PubMed.28513969.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28513969.s2.e0" e2="DDI-PubMed.28513969.s2.e1" /></sentence><sentence text=" It inhibits multiple cytochrome P-450 enzymes and multiple membrane transporters" /><sentence text=" The objective of this study was to evaluate the effect of steady-state faldaprevir on the pharmacokinetics (PK) of a single dose of atorvastatin or rosuvastatin"><entity charOffset="133-145" id="DDI-PubMed.28513969.s4.e0" text="atorvastatin" /><entity charOffset="149-161" id="DDI-PubMed.28513969.s4.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.28513969.s4.e0" e2="DDI-PubMed.28513969.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28513969.s4.e0" e2="DDI-PubMed.28513969.s4.e1" /></sentence><sentence text=" In this single-center, open-label, fixed-sequence crossover study, 33 healthy adult male and female volunteers were given either atorvastatin 10 mg (n = 16) or rosuvastatin 10 mg (n = 17) on day 1"><entity charOffset="130-142" id="DDI-PubMed.28513969.s5.e0" text="atorvastatin" /><entity charOffset="161-173" id="DDI-PubMed.28513969.s5.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.28513969.s5.e0" e2="DDI-PubMed.28513969.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28513969.s5.e0" e2="DDI-PubMed.28513969.s5.e1" /></sentence><sentence text=" Subjects subsequently received 240 mg twice daily of faldaprevir (loading dose) on day 5, followed by 240 mg faldaprevir once daily from day 6 to day 10, with an additional single dose of atorvastatin (10 mg) or rosuvastatin (10 mg) given on day 10"><entity charOffset="54-65" id="DDI-PubMed.28513969.s6.e0" text="faldaprevir" /><entity charOffset="110-121" id="DDI-PubMed.28513969.s6.e1" text="faldaprevir" /><entity charOffset="189-201" id="DDI-PubMed.28513969.s6.e2" text="atorvastatin" /><entity charOffset="213-225" id="DDI-PubMed.28513969.s6.e3" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.28513969.s6.e0" e2="DDI-PubMed.28513969.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28513969.s6.e0" e2="DDI-PubMed.28513969.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28513969.s6.e0" e2="DDI-PubMed.28513969.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28513969.s6.e0" e2="DDI-PubMed.28513969.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28513969.s6.e1" e2="DDI-PubMed.28513969.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28513969.s6.e1" e2="DDI-PubMed.28513969.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28513969.s6.e1" e2="DDI-PubMed.28513969.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28513969.s6.e2" e2="DDI-PubMed.28513969.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28513969.s6.e2" e2="DDI-PubMed.28513969.s6.e3" /></sentence><sentence text=" PK samples for the statins were collected on days 1-3 and days 10-12" /><sentence text=" Concomitant administration with faldaprevir led to approximately 9-fold and 34-fold increases in AUC0-∞ and Cmax , respectively, of atorvastatin and approximately 15-fold and 33-fold increases in AUC0-∞ and Cmax , respectively, of rosuvastatin, compared with the statins given alone"><entity charOffset="33-44" id="DDI-PubMed.28513969.s8.e0" text="faldaprevir" /><entity charOffset="133-145" id="DDI-PubMed.28513969.s8.e1" text="atorvastatin" /><entity charOffset="232-244" id="DDI-PubMed.28513969.s8.e2" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.28513969.s8.e0" e2="DDI-PubMed.28513969.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28513969.s8.e0" e2="DDI-PubMed.28513969.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28513969.s8.e0" e2="DDI-PubMed.28513969.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28513969.s8.e1" e2="DDI-PubMed.28513969.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28513969.s8.e1" e2="DDI-PubMed.28513969.s8.e2" /></sentence><sentence text=" Exposure to the major metabolites (ortho-hydroxyatorvastatin and N-desmethylrosuvastatin) was increased to a similar magnitude as that of the parent compounds"><entity charOffset="66-89" id="DDI-PubMed.28513969.s9.e0" text="N-desmethylrosuvastatin" /></sentence><sentence text=" The marked drug-drug interaction observed is most likely related to the inhibitory effects of faldaprevir on transporters, particularly hepatic uptake transporters such as OTAP1B1 and OATP1B3"><entity charOffset="95-106" id="DDI-PubMed.28513969.s10.e0" text="faldaprevir" /></sentence><sentence text=" Given the significant increase in exposure to statins in healthy volunteers, coadministration of faldaprevir with statins should be avoided"><entity charOffset="98-109" id="DDI-PubMed.28513969.s11.e0" text="faldaprevir" /></sentence><sentence text="" /></document>